These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21323739)

  • 1. Multiple myeloma: interplay between osteoblastogenesis and adipogenesis.
    Kaiafa G; Dokos C; Hatzitolios A; Savopoulos C
    Eur J Haematol; 2011 May; 86(5):447-8. PubMed ID: 21323739
    [No Abstract]   [Full Text] [Related]  

  • 2. [Proteasome inhibitors for multiple myeloma].
    Yano H; Iida S
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():601-4. PubMed ID: 17476759
    [No Abstract]   [Full Text] [Related]  

  • 3. Proteasome inhibitor holds promise for patients with refractory multiple myeloma.
    Expert Rev Anticancer Ther; 2001 Dec; 1(4):509-10. PubMed ID: 12113081
    [No Abstract]   [Full Text] [Related]  

  • 4. Bortezomib for myeloma -- much ado about something.
    Dispenzieri A
    N Engl J Med; 2005 Jun; 352(24):2546-8. PubMed ID: 15958811
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.
    Fröhlich K; Holle JU; Aries PM; Gross WL; Moosig F
    Ann Rheum Dis; 2011 Jul; 70(7):1344-5. PubMed ID: 21173019
    [No Abstract]   [Full Text] [Related]  

  • 6. The proteasome--an emerging therapeutic target in cancer.
    Mitchell BS
    N Engl J Med; 2003 Jun; 348(26):2597-8. PubMed ID: 12826633
    [No Abstract]   [Full Text] [Related]  

  • 7. 20S ways to apoptosis.
    McConkey DJ
    Nat Chem Biol; 2008 Sep; 4(9):528-9. PubMed ID: 18711380
    [No Abstract]   [Full Text] [Related]  

  • 8. [Bortezomib].
    Simons S; Scheulen ME; Jaehde U
    Dtsch Med Wochenschr; 2006 Feb; 131(5):214-8. PubMed ID: 16440269
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
    Zangari M; Esseltine D; Lee CK; Barlogie B; Elice F; Burns MJ; Kang SH; Yaccoby S; Najarian K; Richardson P; Sonneveld P; Tricot G
    Br J Haematol; 2005 Oct; 131(1):71-3. PubMed ID: 16173965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib in multiple myeloma.
    Faix JD
    N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14507954
    [No Abstract]   [Full Text] [Related]  

  • 11. Multiple myeloma.
    Kyle RA; Rajkumar SV
    N Engl J Med; 2004 Oct; 351(18):1860-73. PubMed ID: 15509819
    [No Abstract]   [Full Text] [Related]  

  • 12. Bortezomib.
    Paramore A; Frantz S
    Nat Rev Drug Discov; 2003 Aug; 2(8):611-2. PubMed ID: 12908468
    [No Abstract]   [Full Text] [Related]  

  • 13. [Proteasome inhibitor bortezomib as an anticancer drug].
    Yasui H; Hideshima T
    Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-angiogenic effect of bortezomib in patients with multiple myeloma.
    Politou M; Naresh K; Terpos E; Crawley D; Lampert I; Apperley JF; Rahemtulla A
    Acta Haematol; 2005; 114(3):170-3. PubMed ID: 16227683
    [No Abstract]   [Full Text] [Related]  

  • 15. Images in clinical Medicine. Bortezomib-induced skin lesions.
    Agterof MJ; Biesma DH
    N Engl J Med; 2005 Jun; 352(24):2534. PubMed ID: 15958809
    [No Abstract]   [Full Text] [Related]  

  • 16. Bortezomib in multiple myeloma.
    Meisler AI
    N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14510013
    [No Abstract]   [Full Text] [Related]  

  • 17. Cancer research. Taking garbage in, tossing cancer out?
    Garber K
    Science; 2002 Jan; 295(5555):612-3. PubMed ID: 11809952
    [No Abstract]   [Full Text] [Related]  

  • 18. Perspective on the current use of bortezomib in multiple myeloma.
    San-Miguel J; Bladé J
    Haematologica; 2006 Jul; 91(7):871-2. PubMed ID: 16818272
    [No Abstract]   [Full Text] [Related]  

  • 19. [Situation of translational research and development of molecular-targeted agents for multiple myeloma].
    Kizaki M
    Nihon Rinsho; 2007 Dec; 65(12):2357-61. PubMed ID: 18069283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New treatment approaches in multiple myeloma.
    Berrebi A
    Isr Med Assoc J; 2005 Dec; 7(12):820-1. PubMed ID: 16382710
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.